TITLE

Review: Combining 2 classes of blood pressure-lowering drugs has an approximately additive effect on systolic blood pressure

AUTHOR(S)
Shantsila, Alena; Lip, Gregory Y. H.; Wald, D. S.
PUB. DATE
August 2009
SOURCE
ACP Journal Club;8/18/2009, Vol. 151 Issue 2, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that combining 2 classes of blood pressure lowering drugs has an approximately additive effect on systolic blood pressure. In the trials, mean placebo-subtracted systolic BP reductions for monotherapies ranged from 6.8 mm Hg for ACE-Is to 9.3 mm Hg for BBsand reductions for drug combinations ranged from 13.9 mm Hg for ACE-I combinations to 18.9 mm Hg for BB combinations
ACCESSION #
44638095

 

Related Articles

  • Sitaxentan: In Pulmonary Arterial Hypertension. Scott, Lesley J. // Drugs;2007, Vol. 67 Issue 5, p761 

    ▴ Sitaxentan is a highly selective endothelin (ET)A receptor antagonist, with an ≈6500 higher affinity for ETA than ETB receptors. In pulmonary arterial hypertension (PAH), elevated ET-1 levels are strongly correlated with disease severity and prognosis. ▴ Sitaxentan 100mg once...

  • Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. Palatini, Paolo; Malacco, Ettore; Di Somma, Salvatore; Carretta, Renzo; Dorigatti, Francesca; Bertocchi, Federico; Mann, Jessica // European Journal of Clinical Pharmacology;Jan2002, Vol. 57 Issue 11, p765 

    Objective: The aim of this study was to measure the time–effect profiles of a once-daily administered valsartan/hydrochlorothiazide combination and amlodipine on blood pressure using various indices derived from 24-h ambulatory blood pressure (BP) monitoring. Methods: Of the 310...

  • Clinical trials of antihypertensives: Nature of control and design. Chakraborty, Bhaswat S. // Indian Journal of Pharmacology;Feb2011, Vol. 43 Issue 1, p13 

    This paper reviews the critical issues in the control and design of antihypertension (anti-HT) clinical trials. The international guidelines and current clinical and biostatistical practices were reviewed for relevant clinical, design, end-point assessments and regulatory issues. The results are...

  • Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial. Fuchs, Flávio D.; Fuchs, Sandra C.; Moreira, Leila B.; Gus, Miguel; Nóbrega, Antônio C.; Poli-de-Figueiredo, Carlos E.; Mion, Décio; Bortoloto, Luiz; Consolim-Colombo, Fernanda; Nobre, Fernando; Coelho, Eduardo Barbosa; Vilela-Martin, José F.; Moreno, Jr., Heitor; Cesarino, Evandro José; Franco, Roberto; Brandão, Andréa Araujo; de Sousa, Marcos R.; Ribeiro, Antônio Luiz Pinho; Jardim, Paulo Cesar; Neto, Abrahão Afiune // Trials;2011, Vol. 12 Issue 1, p65 

    Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had...

  • Allopurinol reduces blood pressure in hypertensive youths.  // Australian Journal of Pharmacy;Apr2009, Vol. 90 Issue 1067, p76 

    The article offers information concerning the findings of a study that allopurinol, a drug that is used for treating excessive build up of uric acid, reduces blood pressure in hypertensive youths. It mentions that allopurinol and placebo treatment for four weeks stabilizes blood pressure of the...

  • Telemetry or How to Increase the Efficacy of the Antihypertensive Treatment. Laszlo, M. I.; Kikeli, P. I.; Preg, Z.; Bocicor, Andreea // Acta Medica Marisiensis;Oct2010, Vol. 56 Issue 5, p457 

    Introduction: Hypertension is a cardiovascular risk factor which according to the SEPHAR study is therapeutically controlled in about 22.3% of patients. Therefore it is imperative to increase the efficiency of treatment in order to improve control of blood pressure. Material and methods: We...

  • The coming epidemic: hypertension in rural Kyrgyzstan, Central Asia. Young, J. H.; Parler, P.; Bristol, B.; Klag, M. J. // Journal of Human Hypertension;Feb2005, Vol. 19 Issue 2, p145 

    Eastern Europe is experiencing an epidemic of cardiovascular disease far outpacing rates in Western Europe. This epidemic was heralded by a precipitous rise in hypertension prevalence. The former Soviet states of Central Asia may be facing a similar epidemic. In order to access this threat, we...

  • Paracetamol raises BP risk.  // Pulse;3/8/2007, Vol. 67 Issue 9, p13 

    The article discusses the results of the study conducted by Gary Curhan of Harvard Medical School which show the potential of paracetamol to increase blood pressure. According to Curhan, the widespread use of medications and high prevalence of hypertension may have important public health...

  • Non-dipping BP 'needs aggressive therapy'.  // GP: General Practitioner;5/15/2009, p10 

    The article reports on a research of patients with resistant hypertension (RH). In this study, researchers performed 24-hour blood pressure (BP) monitoring on 556 patients with RH. The research suggested that patients whose BP does not fall overnight are at increased risk of adverse outcomes...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics